GlobeNewswire by notified

DNO Finds Oil at Ofelia

Share

Oslo, 26 August 2022 – DNO ASA, the Norwegian oil and gas operator, today confirmed an oil discovery on the Ofelia prospect in the Norwegian North Sea license PL929 in which the Company holds a 10 percent interest. The well encountered a 73-meter oil column in Lower Cretaceous Agat Formation sandstones of moderate to good reservoir quality. Preliminary estimates of gross recoverable resources are in the range of 16-39 million barrels of oil equivalent. In addition, upsides have been identified in both the Agat Formation and the overlying Kyrre Formation.

The partners, which in addition to the Company’s wholly-owned subsidiary DNO Norge AS, include license operator Neptune Energy Norge AS, Wintershall Dea Norge AS, Pandion Energy AS and ABP Norway AS, will consider development of the discovery with a tieback to the Neptune-operated Gjøa platform 15 kilometers to the south.

With Ofelia, DNO racks up its third recent exploration success in the Troll-Gjøa area in the North Sea alongside the 2022 Kveikje (DNO 29 percent) and 2021 Røver Nord discoveries (DNO 20 percent). The Company is one of the largest holders of acreage in what has become an exploration hotspot on the Norwegian continental shelf, with several drill-ready prospects close to existing infrastructure. The next of these prospects to be tested, Røver Sør, will be drilled in the fourth quarter of 2022 within the Røver Nord discovery license.

For further information, please contact:
Media: media@dno.no
Investors: investor.relations@dno.no

DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

DSV, 1106 - SHARE BUYBACK IN DSV A/S7.5.2024 09:53:54 CEST | Press release

Company Announcement No. 1106 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-3145,0001,013.69146,985,0504:29 April 202475,0001,014.7176,103,2505:30 April 20247,0001,002.427,016,9406:1 May 20249,680993.049,612,6277:2 May 20247,320990.197,248,1918:3

Coloplast Finance B.V. - Interim Financial Report, H1 2023/247.5.2024 09:51:03 CEST | Press release

H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continued good momentum in Chronic Care. Ostomy Care growth was driven by broad-based contribution from Emerging markets and Europe, compensating for lower growth in the US which was held back by order phasing and now expected to be H2 weighted. Continence Care growth was driven by intermittent catheters, including good contribution from LujaTM. Voice and Respiratory Care had a strong Q2, driven by double-digit growth in both laryngectomy and tracheostomy.Growth in Advanced Wound Dressings was broad-based

Suspension af udvalgte afdelinger i Værdipapirfonden Sparinvest fortsætter den 7. maj 20247.5.2024 09:44:09 CEST | pressemeddelelse

Det skal oplyses, at suspension af nedenstående afdelinger forlænges i dag den 7. maj 2024. Suspensionen vil blive ophævet, når der igen kan stilles korrekt indre værdi i de enkelte afdelinger. ISINOrder book codeAfdelingsnavn før ændringAfdelingsnavn efter ændringDK0060254043SPVINONye obligationsmarkederINDEX Emerging Market Bonds LokalvalutaDK0060254126SPVINOAKKKLANye obligationsmarkeder Akk. – KL AINDEX Emerging Market Bonds Lokalvaluta Akk. – KL A Suspensionen kommer i forlængelse af den udmeldte og planlagte omlægning i foreningen jf. børsmeddelelser fra den 19. april 2024 og 1. maj. Eventuel henvendelse vedrørende denne meddelelse kan rettes til npa.pm@nykredit.dk cc jna@nykredit.dk. Med venlig hilsen Morten Skipper Direktør, ID-Sparinvest, Filial af Sparinvest S.A., Luxembourg

HiddenA line styled icon from Orion Icon Library.Eye